Please switch to a supported browser to continue using this website.Consider using the latest version of Google Chrome or Microsoft's Edge to view this website.
CSL is a global biotechnology leader which develops and delivers innovative medicines that save lives, protects public health and helps people with life-threatening medical conditions live full lives.
The Commonwealth Serum Laboratories was established in Australia in 1916 to service the health needs of a nation isolated by war. Over the ensuing years CSL provided Australians with rapid access to 20th century medical advances including insulin and penicillin, and vaccines against influenza, polio and other infectious diseases.
CSL Limited is listed on the Australian Securities Exchange (ASX)
CSL Limited listed on the ASX on 3 June 1994.
CSL Limited trades under the ticker code: CSL
All shares listed on the ASX can be bought or sold through a broker or trading platform.
For more information on how to find the right broker of trading platform, visit the ASX website at www.asx.com.au
The minimum amount of shares under ASX listing rules is A$500 worth of shares.
CSL commenced a Level 1 ADR program in 2014 sponsored by the Bank of New York Mellon.
CSL’s ADRs are traded on the over-the-counter (OTC) securities market in the US under the symbol CSLLY and CUSIP: 12637N204. Two ADRs represent one ordinary share in CSL.
See how we are driven by our promise.
View our Board and Management here.
View our corporate governance here.